Rubric Capital Management (New York)’s Mereo BioPharma MREO Stock Holding History

Rubric Capital Management (New York)’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.86M	Hold	15,307,347	–	–	0.04%	81
2026 Q1	$5.05M	Hold	15,307,347	–	–	0.05%	77
2025 Q4	$6.38M	Hold	15,307,347	–	–	0.08%	71
2025 Q3	$31.5M	Hold	15,307,347	–	–	0.36%	47
2025 Q2	$41.5M	Hold	15,307,347	–	–	0.63%	39
2025 Q1	$34.4M	Hold	15,307,347	–	–	0.62%	37
2024 Q4	$53.6M	Hold	15,307,347	–	–	0.69%	30
2024 Q3	$62.9M	Hold	15,307,347	–	–	1.03%	25
2024 Q2	$55.1M	Buy	15,307,347 +1,754,350	+13%	+$5.68M	1.44%	28
2024 Q1	$44.7M	Hold	13,552,997	–	–	1.32%	27
2023 Q4	$31.3M	Buy	13,552,997 +1,936,877	+17%	+$3.7M	0.65%	33
2023 Q3	$15M	Hold	11,616,120	–	–	0.56%	41
2023 Q2	$15.3M	Buy	11,616,120 +1,250,000	+12%	+$1.45M	0.66%	40
2023 Q1	$7.33M	Hold	10,366,120	–	–	0.19%	59
2022 Q4	$7.77M	Hold	10,366,120	–	–	0.34%	62
2022 Q3	$8.93M	Sell	10,366,120 -6,390,000	-38%	-$7.82M	0.45%	48
2022 Q2	$18.8M	Buy	16,756,120 +1,756,120	+12%	+$1.36M	0.99%	32
2022 Q1	$16.8M	Buy	15,000,000 +85,553	+0.6%	+$111K	0.61%	40
2021 Q4	$23.9M	Buy	14,914,447 +3,614,447	+32%	+$7.23M	1.13%	31
2021 Q3	$27.3M	Buy	11,300,000 +5,639,392	+100%	+$14.9M	0.76%	30
2021 Q2	$17.9M	Buy	5,660,608 +2,745,747	+94%	+$9.21M	1.13%	37
2021 Q1	$9.82M	Buy	2,914,861 +1,061,444	+57%	+$3.75M	0.57%	47
2020 Q4	$6.63M	Buy	+1,853,417	New	+$4.64M	0.49%	48

Other funds holding MREO

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

Rubric Capital Management (New York)'s MREO Position: Q2 2026 in Review

Rubric Capital Management (New York) held its Mereo BioPharma (MREO) position steady in Q2 2026 at 15,307,347 shares worth $4.86M. The position accounts for 0.04% of the portfolio, ranked #81.

Rubric Capital Management (New York) first reported a position in MREO in Q4 2020 and has held it in 23 quarters since. The position peaked at $62.9M in Q3 2024. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Rubric Capital Management (New York) held 15,307,347 shares of Mereo BioPharma worth $4.86M as of Q2 2026.
Rubric Capital Management (New York) left its Mereo BioPharma share count unchanged in Q2 2026.
Mereo BioPharma made up 0.04% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #81 holding.
Rubric Capital Management (New York) first reported a position in Mereo BioPharma in Q4 2020 and has held it in 23 quarters since.
Rubric Capital Management (New York)'s Mereo BioPharma position peaked at $62.9M in Q3 2024.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.